Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06984562 · ClinicalTrials.gov registry record · NA
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
A NA study of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA), sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06984562: Recruiting NA study of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA), sponsored by Fox Chase Cancer Center.
NCT06984562 is a NA study of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA) that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06984562, a NA study of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA), is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer. The main questions the study aims to answer are: * Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor? * Can ART help reduce the side effects that participants may experience during treatment? Participants will: * Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning. * Have a tumor biopsy, which involves taking a small sample of tissue from the cancer. * Receive 5 radiation treatments every other day over a 2-week period. * Provide blood samples before, during, and after your radiation treatment.
Conditions Studied
Interventions
- RADIATION Adaptive Radiation Therapy
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-08-20 |
| Est. Completion | 2029-08-01 |
| Phase | NA |
What NCT06984562 shows while recruiting
NCT06984562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA) appearing as the primary indexed condition, and to 1 intervention - of which Adaptive Radiation Therapy is the first listed.
NCT06984562 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06984562 about?
NCT06984562 is a clinical study titled "Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer". The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer. The main questions the study aims to answer are: * Can ART improve how well radiation therapy targets the most aggressive cancer cells...
What is the current status of trial NCT06984562?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2025-08-20. Estimated completion is 2029-08-01.
What conditions does trial NCT06984562 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA).
What interventions are being tested in trial NCT06984562?
The interventions under investigation include: Adaptive Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06984562?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06984562 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06984562's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI